Axillary desmoid-type fibromatosis: a rare clinical presentation, histopathological correlation, and literature review Authors: Majed AL-Mourgi, Anwar Shams, Shorouq Mohammed Published: 2026 ABSTRACT BackgroundDesmoid tumours are rare soft-tissue tumours arising from mesenchymal tissue and exhibiting local invasiveness, although they don’t metastasize. These tumours present variably and follow an unpredictable course, ranging from asymptomatic to locally aggressive with excruciating symptoms. Surgical intervention is indicated for symptomatic cases, while indolent cases benefit from close surveillance. Recently, the use of systemic approaches to the management of desmoid tumours has increased. These include γ-secretase inhibitors, which have shown encouraging therapeutic results in the treatment of progressive, refractory cases. Nonetheless, due to the disease's rarity, managing DT remains challenging, and updating the field with current knowledge is warranted. Our case presents a rare axillary desmoid tumour, for which surgical resection was chosen and optimized to achieve complete clearance while preserving upper-limb function.Case presentationHerein, we present a rare case of desmoid-type fibromatosis in the right axillary region of a young, otherwise healthy female. Surgical resection of the mass was performed without intra- or postoperative complications, with the aim of preserving upper-limb function and motion. Postoperative follow-up over 18 months showed no clinical or radiological evidence of tumour recurrence, with full preservation of upper-limb function and motion.ConclusionDesmoid tumours of the axilla are clinically challenging, requiring a careful balance between complete resection and functional preservation. Recently, active surveillance has been used as the primary management for desmoid tumour cases and has shown spontaneous regression without the need for intervention. However, our case demonstrates that a surgical approach can still achieve excellent local control and long-term disease-free survival without functional impairment. It also provides live evidence underscoring the valuable role of surgery in managing symptomatic or progressive tumours in complex anatomical locations. Background Desmoid-type fibromatosis, or desmoid tumour (DT), is a rare disease that accounts for less than 3% of all soft tissue tumours [1–3] and approximately 0.03% of all neoplasms [4]. It originates from deep connective tissues and can invade adjacent structures, though it lacks the capacity for distant metastasis [5–7]. The clinical scenarios of DT can range from asymptomatic disease to intolerable presentations that affect vital functions and the patient's life [8, 9]. Based on next-generation sequencing, DT has been classified as sporadic in approximately 85% to 90% of cases, due to dysregulation of the Wnt pathway and somatic mutations in the CTNNB1 gene [10, 11]. The other type of DT accounts for approximately 5%−10% of cases and is associated with a germline mutation in familial adenomatous polyposis (FAP) [11–13]. Several risk factors were linked to the growth of DT, including changes in female sex hormones [3]. Indeed, DT has a predilection for females and is reported to occur in association with pregnancy and during the use of hormonal replacement therapy [3]. Additionally, trauma (such as surgery or breast implants) and genetic background are other risk factors that play a role in the development of desmoid tumours [3, 14]. Desmoid tumours primarily affect the abdominal wall, mesentery, and extremities, as well as areas near the neurovascular bundle [11, 13]. The extra-abdominal organs, such as those in the chest, head, and neck regions, are relatively uncommon sites [11, 13]. Treatment guidelines for DT remain a clinical challenge in some cases because of the disease's rarity and inadequate clinical knowledge [7, 9, 15, 16]. In this context, patients with indolent disease are often advised to undergo close, vigilant observation [5]. In clinically symptomatic patients, upfront resection has been a drawback, with limited use due to elevated recurrence rates [5, 17]. In recent years, efforts have been significantly directed toward advancing medical management [5, 9]. Thus, managing desmoid tumours remains controversial, presenting challenges that require ongoing updates to the current knowledge and advances in treatment for this sporadic and complex condition. In this study, we reported a rare case of axillary DT and described the course of our management plan. We also discussed the available therapeutic modalities for desmoid fibromatosis, focusing on systemic treatments and potential druggable agents. Case presentation Medical and surgical history A 33-year-old female patient was referred to the thoracic surgery clinic for evaluation of a right axillary lump that had been present for six months. The patient initially presented to outside institutions, where a fine-needle aspiration (FNA) was obtained, demonstrating bland spindle cells arranged in long, sweeping fascicles with minimal cytologic atypia, set in a collagenous stroma. No mitotic activity was observed, and the samples stained positively for beta-catenin, SMA, and CD34, findings highly consistent with a diagnosis of desmoid fibromatosis. Next, the patient was transferred to our institution for definitive management; therefore, a confirmatory core-needle biopsy was deemed unnecessary at our center. According to the patient's history, the lump is located in the axillary area, is progressively growing, and is painful with mobilization. The patient is medically stable, with no positive family history of malignancies. She had bilateral breast implant surgeries four years ago. On physical examination, a solid lump was palpable in the right axillary region. It was tender on palpation, immobilized, and associated with limited movement of the right upper arm. The skin over the mass remained intact, and there were no signs of lymphadenopathy. The patient underwent an MRI-T1 of the right shoulder and chest. The axial and coronal MRI views showed a partially ill-defined hypoechoic soft-tissue mass in the right axillary fold that avidly and homogenously enhanced post-contrast. The non-contrast MRI scan revealed no calcifications, hemorrhages, or other abnormalities (Fig. 1).Fig. 1MRI-Scan of the chest showing the desmoid tumour lesion on the right axillary side, (A) coronal and (B) axial sections MRI-Scan of the chest showing the desmoid tumour lesion on the right axillary side, (A) coronal and (B) axial sections Surgical procedure Due to increased lump growth and tenderness, the patient underwent surgical excision to prevent neurovascular complications and restore upper-limb range of motion. The axillary vault was exposed via a 5 cm longitudinal incision directly over the mass. The tumour was carefully detached from surrounding tissues using sharp and blunt dissection. Although the dissection was technically challenging due to dense tissue adherence, the tumour was successfully isolated and separated from adjacent vital neurovascular structures, including the brachial plexus, axillary artery, and axillary vein. These structures were continuously visualized and protected throughout the procedure. Dissection of the tumour from the neighbouring muscular boundaries—specifically the pectoralis major, subscapularis, and latissimus dorsi—was achieved using electrocautery with less difficulty. In addition to the resected mass, an additional cavity margin was excised and submitted separately to histopathology to secure the closest definitive surgical clearance margin of 3 mm. An adjacent lymph node adherent to the tumour was excised en bloc with the primary specimen, necessitating its removal to ensure a clear surgical margin. After careful haemostasis, the operation was completed successfully with no vascular or nerve injuries. A Jackson-Pratt drain was placed through a new stab incision, and the wound was closed in anatomical layers. The patient was moved to the recovery area in stable condition without postoperative complications. A referral to medical oncology was arranged to evaluate the potential for radiotherapy. The patient has been followed clinically and radiologically for 18 months. She demonstrated significant improvement in upper-limb function and a pain-free range of motion. There was no evidence of recurrence, and no adjuvant radiation therapy was required. Histopathology report Representative sections from the two containers of the axillary mass and the en bloc lymph node were sent for pathological evaluation. A gross pathological assessment of the axillary mass specimen revealed a single, relatively circumscribed, grayish mass measuring 6.5 cm × 4.2 cm × 3 cm, designated as undesignated (Fig. 2). On histopathological examination, the initial inked margin of the primary removed specimen showed tumour infiltration, and the serial cut section showed a whitish-tan homogeneous appearance. However, an evaluation of additional cavity margins, submitted separately, confirmed they were free of malignancy. Collectively, the final closest definitive surgical clearance was 3 mm, thus ensuring a microscopically negative final margin. Multiple sections of the axillary mass were submitted in eight cassettes. Microscopic examination of the axillary mass demonstrated proliferation of bland spindle cells with thin blood vessels and focal areas of hemorrhage, infiltrating the surrounding skeletal muscle and adipose tissue, with inked margins (Figs. 3A – 3D). No nuclear hyperchromatism, minimal cytologic atypia, and low mitotic activity were observed, as demonstrated in Figs. 3E–3F. A final diagnosis of desmoid-type fibromatosis was confirmed, with positive nuclear staining of beta-catenin (Fig. 3G). In addition, the en bloc lymph node was submitted in two cassettes and exhibited multiple grayish-tan tissue fragments measuring a combined size of 2 cm × 1.8 cm × 0.8 cm, while the entangled, rubbery node measured 1.3 × 1 × 0.8 cm. Microscopic examination of the en bloc lymph node revealed stratified squamous epithelium of skin with underlying sebaceous glands and skin adnexa, with abundant long nerve bundles displaying adherent tumour tissue (Fig. 3H).Fig. 2Postoperative resection of the tumourFig. 3The H & E histopathological examination of the axillary mass; A & B The desmoid fibromatosis is seen infiltrating between the skeletal muscle fibres. C & D Vascular micro hemorrhages showing extraverted red blood cells with infiltrated inked surgical margins. E Long sweeping fascicles with elongated spindled cells of uniform appearance with inconspicuous nucleoli, pale cytoplasm and intervening thin elongated vessels. F Storiform and whorled appearances were identified, with no cytologic atypia. G A beta-catenin immunostaining shows nuclear positivity, supporting the diagnosis of desmoid-type fibromatosis. H The neoplasm is seen entrapping the perineural bundles. Magnification power is 40x, and the scale bar is 100um Postoperative resection of the tumour The H & E histopathological examination of the axillary mass; A & B The desmoid fibromatosis is seen infiltrating between the skeletal muscle fibres. C & D Vascular micro hemorrhages showing extraverted red blood cells with infiltrated inked surgical margins. E Long sweeping fascicles with elongated spindled cells of uniform appearance with inconspicuous nucleoli, pale cytoplasm and intervening thin elongated vessels. F Storiform and whorled appearances were identified, with no cytologic atypia. G A beta-catenin immunostaining shows nuclear positivity, supporting the diagnosis of desmoid-type fibromatosis. H The neoplasm is seen entrapping the perineural bundles. Magnification power is 40x, and the scale bar is 100um Discussion and conclusions Two recognized clinical groups have provided guidelines for managing DT: the NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesÒ) [18] and policies of the Desmoid Tumour Working Group (DTWG) [19]. A frontline watch-and-wait approach has been used as an initial step for managing asymptomatic patients since the early 2000 s [5, 20–23]. Several studies reported that 20%–60% of DT patients showed spontaneous improvement, either after initial presentation or initial progression, without medical or surgical intervention [11, 24–26]. This approach allows close follow-up of tumour behaviour and spares patients from treatment-associated morbidities, while permitting medical intervention in the event of sudden worsening of the condition [20]. Nevertheless, tumour location (particularly in the extremities), large size (> 5 cm), S45F β-catenin alteration, and pregnancy were considered predictors of failure of active surveillance [20]. Historically, surgical resection was performed in patients with clinical symptoms or functional impairment [5, 20]. Yet, postoperative complications, the need for complex reconstruction, and a high recurrence rate were drawbacks of this approach [9, 17, 27, 28]. Notably, post-surgical local recurrence remains a challenge, with a reported rate of 20–45% [20]. In fact, approximately 60% of cases experienced disease relapse within 5 years [20, 29]. Several factors influence the risk of recurrence, including patient age (particularly in young patients), tumour location (particularly at extra-abdominal sites), hormonal exposures, surgical margin status, trauma, and genetic variations [20]. According to NCCN guidelines, surgical intervention is reserved for alleviating symptoms, protecting vital organs, or preserving normal function and movement [9, 18]. Additionally, failure of active surveillance, sustained progression despite multiple medical treatments, and critical anatomical considerations are important indications for surgical resection [20, 26]. Because post-surgical local recurrence is considered high, the aim of surgery should be to achieve a complete macroscopic resection with margins as free as possible [26]. Herein, we present a case of desmoid-type fibromatosis of the axilla in a 33-year-old female with a past history of breast surgery. The patient presented with a painful right axillary lump that restricted upper-limb movement, making surgical resection the optimal option. While active surveillance is appropriate for asymptomatic patients, it is less suitable when symptoms impair quality of life. Compared with systemic therapy, surgery provides more immediate and effective symptom relief. Thus, despite the risk factors for recurrence in this patient (female sex, young age, breast implants, and tumour location), surgery is still reasonable when controlling symptoms and improving function is the primary goal [9, 18]. Furthermore, the patient presented with a large tumour (6.5 cm × 4.2 cm × 3 cm), and, in addition to the tumour location, these factors are predictive of failure of the active surveillance approach. To limit the risk of recurrence [26], extra margins were taken separately after removal of the main mass, which was reviewed separately and showed no infiltration, confirming a negative margin. Notably, the surgical margin plays an important role in predicting the risk of tumour relapse and in selecting adjuvant therapy. Positive margins in DT were associated with a 1.78-fold increased risk of relapse [9]. Because most positive margins remain stable, intensive active surveillance would be prioritized over adjuvant therapy or re-excision [30]. Intensive active surveillance involves monitoring disease progression with imaging every 3–6 months (per the standard protocol, every 6–12 months). Few reported DT cases (~ 8) were diagnosed in the axillary region worldwide, as shown in Table 1. Consistent with our case, surgical resection of the tumour was the initial management in all cases (Table 1), except when the lesion was not amenable to surgery (complex anatomical site), in which case medical therapy (Sorafenib, tyrosine kinase inhibitors) was the optimal option [31]. In agreement with our patient, most of these cases showed no evidence of tumour recurrence during the follow-up period (2 months to 5 years) [31–35]. On the other hand, some of these cases [36–38] experienced post-surgical tumour recurrence (2 to 10 months after surgery). That was associated with a massive invasion of the surrounding structures, which was treated with either radiotherapy [36, 37] or medical therapy (tamoxifen and celecoxib) [38], with no evidence of recurrence thereafter.Table 1Description of desmoid tumour cases detected in the axilla worldwidePatientAge/SexSite of the desmoid tumourTreatment of the desmoid tumorYear of publicationRef150Y/FDesmoid tumour of the axilla (the left upper outer quadrant of axillary tail)Surgical resection1976[32]232Y/M1- Desmoid tumour in the left pectoral region(primary)2- Recurrent desmoid tumour of the axilla (the left axilla adherent to the upper thoracic spine and supplied by branches of the sublavien artery)1-Surgical resection(primary)2-Radiotherapy (recurrence)1979[36]366Y/MDesmoid type fibromatosis of the axilla (the left axilla adherent to periosteum of the acromion and infiltrated to pectoralis major, minor, and biceps)Surgical resection1980[33]457Y/M1-Desmoid tumour of the axilla (the left axilla posterior to pectoralis major and adherent to blood vessels and nerves) (primary)2- Recurrent DT in the fourth rib in the same field then in the ulner side of the left forearm, then the wrist1-Surgical resection(primary)2-Radiotherapy (recurrence)1983[37]557Y/F1-Aggressive desmoid type fibromatosis of the axilla (the right axilla with a total of extra pleural growth) (primary)2-Local recurrence of DT1-Surgical resection(primary)2-Medical, tamoxifen and colcoxib (recurrence)2014[38]654Y/FAggressive desmoid type fibromatosis of the axilla (the left axilla deep into pectoralis major, brachial plexus, subscapularis, latissimus dorsi, teres minor, and scapula)Surgical resection2018[34]718Y/MDesmoid type fibromatosis of the axilla (the left axilla, extended up to subclavian vessels, scapular area and chest wall up to nipple with irregular margin and fibrous consistency)Surgical resection2019[35]831Y/FDesmoid tumour of the axilla (the left axilla, intercalating between the teres major and teres minor)Sorafinib followed bysurgical resection2022[31] Table 1Description of desmoid tumour cases detected in the axilla worldwidePatientAge/SexSite of the desmoid tumourTreatment of the desmoid tumorYear of publicationRef150Y/FDesmoid tumour of the axilla (the left upper outer quadrant of axillary tail)Surgical resection1976[32]232Y/M1- Desmoid tumour in the left pectoral region(primary)2- Recurrent desmoid tumour of the axilla (the left axilla adherent to the upper thoracic spine and supplied by branches of the sublavien artery)1-Surgical resection(primary)2-Radiotherapy (recurrence)1979[36]366Y/MDesmoid type fibromatosis of the axilla (the left axilla adherent to periosteum of the acromion and infiltrated to pectoralis major, minor, and biceps)Surgical resection1980[33]457Y/M1-Desmoid tumour of the axilla (the left axilla posterior to pectoralis major and adherent to blood vessels and nerves) (primary)2- Recurrent DT in the fourth rib in the same field then in the ulner side of the left forearm, then the wrist1-Surgical resection(primary)2-Radiotherapy (recurrence)1983[37]557Y/F1-Aggressive desmoid type fibromatosis of the axilla (the right axilla with a total of extra pleural growth) (primary)2-Local recurrence of DT1-Surgical resection(primary)2-Medical, tamoxifen and colcoxib (recurrence)2014[38]654Y/FAggressive desmoid type fibromatosis of the axilla (the left axilla deep into pectoralis major, brachial plexus, subscapularis, latissimus dorsi, teres minor, and scapula)Surgical resection2018[34]718Y/MDesmoid type fibromatosis of the axilla (the left axilla, extended up to subclavian vessels, scapular area and chest wall up to nipple with irregular margin and fibrous consistency)Surgical resection2019[35]831Y/FDesmoid tumour of the axilla (the left axilla, intercalating between the teres major and teres minor)Sorafinib followed bysurgical resection2022[31] Description of desmoid tumour cases detected in the axilla worldwide 1- Desmoid tumour in the left pectoral region (primary) 2- Recurrent desmoid tumour of the axilla (the left axilla adherent to the upper thoracic spine and supplied by branches of the sublavien artery) 1-Surgical resection (primary) 2-Radiotherapy (recurrence) 1-Desmoid tumour of the axilla (the left axilla posterior to pectoralis major and adherent to blood vessels and nerves) (primary) 2- Recurrent DT in the fourth rib in the same field then in the ulner side of the left forearm, then the wrist 1-Surgical resection (primary) 2-Radiotherapy (recurrence) 1-Aggressive desmoid type fibromatosis of the axilla (the right axilla with a total of extra pleural growth) (primary) 2-Local recurrence of DT 1-Surgical resection (primary) 2-Medical, tamoxifen and colcoxib (recurrence) Sorafinib followed by surgical resection In recent years, significant efforts have focused on developing targeted therapies and other modalities to reduce post-surgical recurrence rates and improve patient prognosis [5]. Systemic treatments include chemotherapy (e.g., methotrexate), targeted agents (e.g., tyrosine kinase inhibitors), hormonal antagonists (e.g., tamoxifen), and nonsteroidal anti-inflammatory medications (e.g., celecoxib) [39–43]. However, the latter two systemic treatments demonstrated limited clinical activity, as shown in a phase 2 trial in which the objective response rates of these agents approached those of the placebo arm [41]. Accordingly, the consensus guidelines from DTWG and NCCN have downgraded their therapeutic roles in the management of DT [44, 45]. Other treatment modalities include locoregional therapies such as cryoablation (for locally advanced disease), radiotherapy (select cases for incomplete surgical resection (R1) and recurrent disease), focused ultrasound and microwave radiofrequency (for DT in children) [39–43, 46], and isolated limb perfusion (ILP) (for DT of the extremities) [47]. Furthermore, interventional radiology-based therapies include thermal and chemical ablation, as well as arterial chemoembolization [20]. Recently, the γ-secretase inhibitor nirogacestat has been at the forefront of treatment for patients with progressive DT. It has been approved by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) following the phase 3 DeFi trial [48, 49]. Initiation of nirogacestat in patients with relapsing-progressive DT refractory to medical treatment resulted in a notable reduction in tumour size and a favourable safety profile [49]. Another γ-secretase inhibitor, varegacestat, showed potent therapeutic efficacy and favourable patient prognosis in the phase 3 RINGSUDE trial [50]. Alterations in Wnt/β-catenin signalling contribute significantly to the pathogenesis of DT. An early trial (NCT05919264) showed that zolucatetide, a direct inhibitor of the β-catenin/TCF interaction, demonstrated meaningful anti-tumour efficacy [51]. Zolucatetide achieved a 100% disease control rate and an 80% objective response rate, including among patients resistant to γ-secretase inhibitors [51]. In summary, the lack of a standard therapeutic strategy for DT stems from the disease's rarity and several challenges. These include the disease's complexity and heterogeneity, its size and location, and the functional impairment associated with it [52, 53]. Moreover, patient age and comorbidities [44], the risk of recurrence, diagnostic challenges, limited public awareness, and a shortage of specialized clinicians [5, 9] also contribute to the disease burden [9]. As noted, the management of DT is not one-size-fits-all; to frame the therapeutic algorithm for DT, further investigations are warranted to link clinical presentations with the patient’s molecular background. Furthermore, a multidisciplinary team, including medical oncology, surgical oncology, and interventional radiology, should weigh the benefits and risks of the selected treatment. This approach would provide a precise, personalized plan for each clinical case, enabling appropriate treatment delivery, reducing the risk of drug toxicity, and improving patient prognosis.